(Q84516280)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22760478%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

title

New disease-modifying therapies and new challenges for MS (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22760478%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

Vijayshree Yadav

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22760478%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Dennis Bourdette

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22760478%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

publication date

1 October 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22760478%20AND%20SRC:MED&resulttype=core&format=json

Current Neurology and Neuroscience Reports

6 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22760478%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22760478%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22760478%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

489-491

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22760478%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11910-012-0295-2

6 February 2020

exact match

0 references

cites work

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

12 December 2020

Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?

1 reference

12 December 2020

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

12 December 2020

Primary varicella zoster infection associated with fingolimod treatment

1 reference

12 December 2020

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis

1 reference

12 December 2020

Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies

1 reference

12 December 2020

Delayed fingolimod-associated asystole

1 reference

12 December 2020

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

1 reference

12 December 2020

Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.

1 reference

12 December 2020

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Anti-JC virus antibodies: implications for PML risk stratification

1 reference

12 December 2020

Risk stratification and patient counseling for natalizumab in multiple sclerosis

1 reference

12 December 2020

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

12 December 2020

Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology

1 reference

12 December 2020